.png){kind=icon}
.png){kind=icon}
Return
Interobserver Agreement in Acute Toxicity Assessment During Head and Neck Radiotherapy/Chemoradiotherapy: Implications for Endpoint Selection in Clinical Trials
.png){kind=icon}
PRE
AI
S
A
S
A
M
A
A
S
P
A
R
I
R
A
P
K
S
DOI：10.1016/j.ijrobp.2026.07.036.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Acute toxicity is a key endpoint in head and neck radiotherapy (RT) and chemoradiotherapy (CRT) trials and is most commonly reported as maximum toxicity per patient. However, the reproducibility of clinician-reported toxicity grading remains incompletely characterized. We evaluated interobserver agreement in acute toxicity assessment, focusing on maximum toxicity as the primary endpoint.
Journal
I
IF:
6.5
Papers:
4.8W
Citations:
4.2W
Organization
Cited Papers